Markets
Joe Biden debate
(Andrew Caballero Reynolds/Getty Images)

The markets saw the debate too

Here’s their verdict.

6/28/24 2:22PM

It’s always a bit dangerous to try to ascribe specific reasons for any particular market move. But it seems pretty obvious that the shockwaves from Thursday’s US presidential debate are emanating through financial markets on Friday.

Popular opinion suggests that the debate had a decisive winner: Donald Trump.

Just look at how Goldman Sachs’ themed basket of stocks that should do well under a Trump administration is doing today compared to a similar basket of stocks that should benefit from a Democratic White House. It’s outperforming by more than 3 percentage points, the most this year.

On PredictIt, the odds of Trump winning the 2024 presidential election rose from 54% before the debate to as high as 64% during the event.

“President Biden and his team now have much more work to do to win re-election than Trump,” writes Kim Wallace, head of Washington Policy Research at 22V Research. “Biden flubbed softball opportunities from questioners and Trump, shocking Democrats and likely many non-Democrats as well.”

Here’s some of what we’re seeing in markets.

Solar sell-off

The most glaring stock-market reaction seems to be in shares of companies that would benefit from policies associated with Democratic priorities. Solar firms like Maxeon Solar Technologies, Sunnova Energy and First Solarare getting creamed as traders seem to be pricing in higher odds of Trump 2.0.

End of Obamacare?

Likewise, health-insurance companies that’ve built large businesses around the Affordable Care Act’s insurance plan exchanges are also suffering Friday. Oscar Health, HCA Healthcare and Tenet Healthcareare all taking it on the chin.

Prisons, private education, and coal companies romp

Conversely, companies investors think will do well under a Republican administration surged on Friday; foremost among them were private prison companies GEO Group, and CoreCivic (formerly Corrections Corporation of America), as well as private education firms such as Grand Canyon Education, and private college operator Laureate Education. Finally, coal companies Peabody Energy and Arch Resources had very good days, as some price in roll backs of climate-related Biden administration initiatives.

GSE reform back on the agenda

During his term, Trump backed attempts to privatize the government-sponsored entities Fannie Mae and Freddie Mac. Shares of both are up roughly double digits on Friday.

RIP, Fed independence?

Perhaps the most notable reaction of the day isn’t in the stock market, but rather in the market for US Treasury bonds. Despite really good news on the inflation front — the Fed’s key measure of inflation dropped more than expected to its lowest level since March 2021 — longer-term Treasury bonds tumbled, pushing yields, which move in the opposite direction, sharply higher.

Since long-term bonds typically rise when inflation comes down, this is a bit odd. It seems, at least to me, that some people are pricing in the long-term effect of a second Trump term on the “full faith and credit” of the United States.

Trump allies’ reported plans to fiddle with the Fed’s traditional independence from direct political control would explain some of that move. Efforts, typically by quasi-or-outright dictatorial governments, to control monetary policy usually works out horribly both for investors in those country’s bonds and for the country itself, as surges of serious inflation — see Turkish, Hungarian or Russian inflation rates in recent years — follows from printing money for political reasons.

Of course there are varying explanations for the move in US Treasury yields. The inflation data, though positive, was well telegraphed before its release and in line with economists’ expectations.

And the market could also be pricing in the potential for better growth thanks to more fiscal stimulus in the event of a united Republican government, or higher inflation because of Trump’s tariffs.

Speaking of Russia

One can’t help notice that the ruble — which really isn’t traded on markets much anymore — and Russian stocks were up slightly on the day. Hard to say why, though Trump’s friendliness toward the Kremlin could translate into easing the sanctions the world imposed on Russia for invading and occupying eastern Ukraine, or a potential end to the conflict — as Trump promised would happen if he wins the election, even before his term begins.

Currency confusion

But of course not everything in markets can be perfectly congruent. The most common Wall Street prognostication is that a Trump presidency would lead to a stronger US dollar (primarily because of the risk of tariffs). But the greenback is slightly lower on the day, as judged by the Dollar Spot Index, and lower against every G10 currency besides the Norwegian krone.

More Markets

See all Markets
markets

Broadcom’s post-earnings romp continues on heavy volumes

As Broadcom enjoys a rush of new orders from a major new customer (reported to be OpenAI), it’s also reveling in a flood of traffic into the stock.

Volumes are running at 2.5 times their daily average through 1:20 p.m. ET as traders continue to bid up shares in response to the brighter outlook for 2026 revenues, which sent the stock up 9.4% on Friday.

The chip designer is basking in a flood of price target hikes from Wall Street, with Bank of America, JPMorgan, Argus Research, Citigroup, Bernstein, Deutsche Bank, Morgan Stanley, Barclays, Piper Sandler, Rosenblatt Securities, Wells Fargo, and Susquehanna upping their view on how high shares can go since the company reported earnings last week.

Separately, Taiwanese industry outlet DigiTimes is reporting that orders from several other leading tech companies for custom-made Broadcom chips (or ASICs) are “already in the pipeline.” This report has not been corroborated by our own or any other publication’s reporting to date.

markets

SpaceX spectrum deal sends would-be rivals lower

Shares of struggling satellite services company EchoStar soared Monday, after the company — which had recently tottered close to bankruptcy — announced the sale of some of its wireless spectrum licenses to Tesla CEO Elon Musk’s SpaceX for $17 million.

The sale provides a competitive advantage to Musk’s growing Starlink satellite services business, as the licenses it is acquiring from Echostar allows Starlink to operate ground based broadband and cellphone services, the Wall Street Journal reported.

Entities that stood to be hurt by the emergence of a Musk-led SpaceX Starlink service got hit hard on the news. AST SpaceMobile, which has plans to offer a similar satellite-to-consumer cellular service, tumbled.

So did wireless tower providers like Crown Castle and American Tower. Low cost cellular service provider T-Mobile, which had a deal with SpaceX, also slumped, as Luke noted earlier, along with other large wireless telecommunication services providers.

The wireless telecommunications industry grouping within the S&P 500 was down more than 2.5% shortly after noon, making it the worst performing industry within the S&P 500 on Monday.

Entities that stood to be hurt by the emergence of a Musk-led SpaceX Starlink service got hit hard on the news. AST SpaceMobile, which has plans to offer a similar satellite-to-consumer cellular service, tumbled.

So did wireless tower providers like Crown Castle and American Tower. Low cost cellular service provider T-Mobile, which had a deal with SpaceX, also slumped, as Luke noted earlier, along with other large wireless telecommunication services providers.

The wireless telecommunications industry grouping within the S&P 500 was down more than 2.5% shortly after noon, making it the worst performing industry within the S&P 500 on Monday.

markets

Hims rises, Novo dips after FDA releases “green list” of GLP-1 raw material suppliers

Hims & Hers rose and Novo Nordisk slipped in early trading after the US Food and Drug Administration released a "green list" of foreign GLP-1 ingredient suppliers that it considers in compliance with agency standards.

Some telehealth companies like Hims sell copycat versions of Novo's and Eli Lilly’s blockbuster weight-loss drugs through compounding pharmacies, which take the active ingredients from FDA-approved medications and make adjusted, or "personalized,” versions of the drug for patients.

Novo and Lilly have fought against this, arguing that it infringes on their intellectual property. They've sued smaller telehealth providers, pharmacies, and clinics in lieu of any action against them from the FDA. Instead, the FDA gave compounders a list of suppliers it deems safe.

Recent developments in the cases filed by the drugmakers so far as well as the FDA's recent actions suggest telehealth companies may be in a less risky position than investors previously thought. As of Monday morning, prediction markets pegged the likelihood of a suit from Novo against Hims at 34%, down from about 70% earlier this month.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.